ReWalk Robotics (LFWD) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 11, 2023
Cover [Abstract]
Entity Central Index Key	0001607962
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-36612
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Incorporation State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	3 Hatnufa Street
Entity Address, Address Line Two	Floor 6
Entity Address, City or Town	Yokneam Ilit
Entity Address, Country	IL
Entity Address, Postal Zip Code	2069203
Title of 12(b) Security	Ordinary shares, par value NIS 0.25
Trading Symbol	RWLK
Name of Exchange on which Security is Registered	NASDAQ
City Area Code	972
Local Phone Number	4.959.0123
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,570,788

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 61,883	$ 67,896
Trade receivable, net	532	1,036
Prepaid expenses and other current assets	1,434	649
Inventories	3,027	2,929
Total current assets	66,876	72,510
LONG-TERM ASSETS
Restricted cash and other long-term assets	692	694
Operating lease right-of-use assets	1,250	836
Property and equipment, net	160	196
Total long-term assets	2,102	1,726
Total assets	68,978	74,236
CURRENT LIABILITIES
Current maturities of operating leases liability	624	564
Trade payables	1,781	1,950
Employees and payroll accruals	513	1,282
Deferred revenues	357	301
Other current liabilities	608	685
Total current liabilities	3,883	4,782
LONG-TERM LIABILITIES
Deferred revenues	895	890
Non-current operating leases liability	657	333
Other long-term liabilities	24	66
Total long-term liabilities	1,576	1,289
Total liabilities	5,459	6,071
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS’ EQUITY
Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at March 31, 2023 and December 31, 2022; Issued: 63,145,562 and 63,023,506 shares at March 31, 2023 and December 31, 2022, respectively; Outstanding: 59,482,004 and 60,090,298 shares as of March 31, 2023 and December 31, 2022 respectively	4,445	4,489
Additional paid-in capital	280,152	279,857
Treasury Shares at cost, 3,663,558 and 2,933,208 ordinary shares at March 31, 2023 and December 31, 2022 respectively	(3,007)	(2,431)
Accumulated deficit	(218,071)	(213,750)
Total shareholders' equity	63,519	68,165
Total liabilities and shareholders' equity	$ 68,978	$ 74,236

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Ordinary shares, par value per share	₪ 0.25	₪ 0.25
Ordinary shares, authorized	120,000,000	120,000,000
Ordinary shares, issued	63,145,562	63,023,506
Ordinary shares, outstanding	59,482,004	60,090,298
Treasury stock common shares	3,663,558	2,933,208

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues	$ 1,230	$ 876
Cost of revenues	659	611
Gross profit	571	265
Operating expenses:
Research and development, net	752	907
Sales and marketing	2,484	2,184
General and administrative	1,710	1,462
Total operating expenses	4,946	4,553
Operating loss	(4,375)	(4,288)
Financial expenses (income), net	(78)	24
Loss before income taxes	(4,297)	(4,312)
Taxes on income	24	38
Net loss	$ (4,321)	$ (4,350)
Net loss per ordinary share, basic	$ (0.07)	$ (0.07)
Net loss per ordinary share, diluted	$ (0.07)	$ (0.07)
Weighted average number of shares used in computing net loss per ordinary share, basic	59,515,524	62,493,496
Weighted average number of shares used in computing net loss per ordinary share, diluted	59,515,524	62,493,496

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Ordinary Shares	Additional Paid-in Capital	Treasury Shares	Accumulated deficit	Total
Balance at Dec. 31, 2021	$ 4,661	$ 278,903	$ 0	$ (194,181)	$ 89,383
Balance, shares at Dec. 31, 2021	62,480,163
Share-based compensation to employees and non-employees		153	0	0	153
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees	$ 2	(2)	0	0	0
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, Shares	28,354
Net loss		0	0	(4,350)	(4,350)
Balance at Mar. 31, 2022	$ 4,663	279,054	0	(198,531)	85,186
Balance, shares at Mar. 31, 2022	62,508,517
Balance at Dec. 31, 2022	$ 4,489	279,857	(2,431)	(213,750)	68,165
Balance, shares at Dec. 31, 2022	60,090,298
Share-based compensation to employees and non-employees		304	0	0	304
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees	$ 9	(9)	0	0	0
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, Shares	122,056
Treasury shares	$ (53)	0	(576)	0	(629)
Treasury Shares, Shares	(730,350)
Net loss		0	0	(4,321)	(4,321)
Balance at Mar. 31, 2023	$ 4,445	$ 280,152	$ (3,007)	$ (218,071)	$ 63,519
Balance, shares at Mar. 31, 2023	59,482,004

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows used in operating activities:
Net loss	$ (4,321)	$ (4,350)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	36	53
Share-based compensation	304	153
Deferred taxes	0	1
Foreign currency remeasurement loss	11	0
Changes in assets and liabilities:
Trade receivables, net	504	21
Prepaid expenses, operating lease right-of-use assets and other assets	(1,370)	(706)
Inventories	(119)	(325)
Trade payables	23	81
Employees and payroll accruals	(769)	(465)
Deferred revenues	61	(34)
Operating lease liabilities and other liabilities	407	(137)
Net cash used in operating activities	(5,233)	(5,708)
Cash flows used in investing activities:
Purchase of property and equipment	0	(3)
Net cash used in investing activities	0	(3)
Cash flows from financing activities:
Purchase of treasury shares	(771)	0
Net cash used in financing activities	(771)	0
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash	(11)	0
Decrease in cash, cash equivalents, and restricted cash	(6,015)	(5,711)
Cash, cash equivalents, and restricted cash at beginning of period	68,555	89,050
Cash, cash equivalents, and restricted cash at end of period	62,540	83,339
Supplemental disclosures of non-cash flow information
Classification of inventory to property and equipment, net	0	51
Classification of other current assets to property and equipment, net	0	22
ROU assets obtained from new lease liabilities	513	0
Supplemental cash flow information:
Cash and cash equivalents	61,883	82,632
Restricted cash included in other long-term assets	657	707
Total Cash, cash equivalents, and restricted cash	$ 62,540	$ 83,339

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1: GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013. c. The Company is a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community. The Company has sought to expand its product offerings beyond the SCI Products through internal development and distribution agreements. The Company has developed its ReStore Exo-Suit device, which it began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disability due to stroke. During the second quarter of 2020, the Company signed two separate agreements to distribute additional product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. In the second quarter of 2020, the Company also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023. The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with neurological injury and disability. The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe. d. As of March 31, 2023, the Company incurred a consolidated net loss of $4.3 million and has an accumulated deficit in the total amount of $218.1 million. The Company’s cash and cash equivalent as of March 31, 2023 totaled $61.9 million and the Company’s negative operating cash flow for the three months ended March 31, 2023 was $5.2 million. The Company has sufficient funds to support its operations for more than 12 months following the issuance date of its unaudited condensed consolidated financial statements for the three months ended March 31, 2023. The Company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the successful development and commercialization of its products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenues adequate to support its cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.

UNAUDITED INTERIM CONDENSED CON

UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2023
Unaudited Interim Condensed Consolidated Financial Statements [Abstract]
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2: UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the 2022 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 (the “2022 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the consolidated financial statements for the fiscal year ended December 31, 2022 included in the 2022 Form 10-K, unless otherwise stated.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3: SIGNIFICANT ACCOUNTING POLICIES a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended March 31, 2023 2022 Units placed $ 1,126 $ 778 Spare parts and warranties 104 98 Total Revenues $ 1,230 $ 876 Units placed During the periods for the three months ended March 31, 2023 and 2022, the Company offered five products: (1) ReWalk Personal; (2) ReWalk Rehabilitation; (3) ReStore; (4) MyoCycle; and (5) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023. ReWalk Personal and ReWalk Rehabilitation are SCI Products, which are currently designed for everyday use by paraplegic individuals at home and in their communities. The SCI Products are custom fitted for each user, as well as for use by paraplegic patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReWalk Rehabilitation which is a ReWalk Personal 6.0 product sold with multiple sizes of our adjustable parts to allow different users the ability to train within a clinic. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. The Company also sells Distributed Products that include the MyoCycle, which uses Functional Electrical Stimulation (“FES”) technology, and previously MediTouch tutor movement biofeedback devices. The Company markets the Distributed Products in the United States for use at home or in clinic. On January 31, 2023, the Company terminated the distribution agreement with MediTouch. Units placed includes revenue from sales of SCI Products, ReStore and the Distributed Products. For units placed, the Company recognizes revenue when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model. SCI Products include a five-year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty. The ReStore device is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are sold with an assurance-type warranty ranging from one year to ten years depending on the specific product and part. Contract balances (in thousands) March 31, December 31, 2023 2022 Trade receivable, net of credit losses (1) $ 532 $ 1,036 Deferred revenues (1) (2) $ 1,252 $ 1,191 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the three months ended March 31, 2023, $128 thousand of the December 31, 2022 deferred revenues balance was recognized as revenues. Deferred revenue is composed primarily of unearned revenue related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company’s unearned performance obligations as of March 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.2 million, which will be fulfilled over one to five years. b. Concentrations of Credit Risks: The below table reflects the concentration of credit risk for the Company’s current customers as of the quarter ended March 31, 2023, to which substantial sales were made: March 31, December 31, 2023 2022 Customer A 28 % 27 % Customer B 24 % 13 % Customer C * ) 13 % Customer D * ) 11 % *) Less than 10% The allowance for credit losses is based on the Company’s assessment of the collectability of accounts. The Company regularly assessed collectability based on a combination of factors, including an assessment of the current customer’s aging balance, the nature and size of the customer, the financial condition of the customer, and future expected economic conditions. Trade receivables deemed uncollectable are charged against the allowance for credit losses when identified. As of March 31, 2023 and December 31, 2022, trade receivables are presented net of allowance for credit losses in the amount of $26 thousand. c. Warranty provision For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars Balance at December 31, 2022 $ 92 Provision 87 Usage (90 ) Balance at March 31, 2023 $ 89 d. Basic and diluted net loss per ordinary share: Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive. For the three months ended March 31, 2023 and 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,464,856 and 19,420,894, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect. e. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Financial Instruments In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4: INVENTORIES The components of inventories are as follows (in thousands): March 31, December 31, 2023 2022 Finished products $ 2,519 $ 2,421 Raw materials 508 508 $ 3,027 $ 2,929

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5: COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitments: The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be canceled without penalty. As of March 31, 2023, non-cancelable outstanding obligations amounted to approximately $2.1 million. b. Operating lease commitment: (i) The Company operates from leased facilities in Israel, the United States and Germany. These leases expire in 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (the “CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. (ii) RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates between 2023 and 2026. A subset of the Company’s car leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $21 thousand as of March 31, 2023. The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company's condensed consolidated balance sheets as of March 31, 2023 are as follows (in thousands): 2023 $ 503 2024 638 2025 295 2026 1 Total lease payments 1,437 Less: imputed interest (156 ) Present value of future lease payments 1,281 Less: current maturities of operating leases (624 ) Non-current operating leases $ 657 Weighted-average remaining lease term (in years) 2.18 Weighted-average discount rate 9.9 % Lease expense under the Company’s operating leases was $192 thousand and $179 thousand for the three months ended March 31, 2023 and 2022, respectively. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”). Since the Company’s inception through March 31, 2023, the Company received funding from the IIA in the total amount of $2.3 million. Out of the $2.3 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $349 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. Additionally, the License Agreement requires the Company to pay Harvard royalties on net sales, see Note 6 below for more information about the Collaboration Agreement and the License Agreement. As of March 31, 2023, the Company paid royalties to the IIA in the total amount of $110 thousand. Royalties expenses in cost of revenues were $0 and $3 thousand for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens: As part of the Company’s other long-term assets and restricted cash, an amount of $657 thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party. e. Legal Claims: Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. The outcome of any pending or threatened litigation and other legal matters is inherently uncertain, and it is possible that resolution of any such matters could result in losses material to the Company’s consolidated results of operations, liquidity, or financial condition. Except as otherwise disclosed herein, the Company is not currently party to any material litigation.

RESEARCH COLLABORATION AGREEMEN

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	3 Months Ended
	Mar. 31, 2023
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 6: RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Collaboration Agreement (as amended, the “Collaboration Agreement”) and an Exclusive License Agreement (as amended, the “License Agreement”) with Harvard. The Collaboration Agreement concluded on March 31, 2022. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement required the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of March 31, 2023, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis. The Company has recorded expenses in the amount of $11 thousand and $10 thousand as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three months ended March 31, 2023, and 2022, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 7: SHAREHOLDERS’ EQUITY a. Share option plans: As of March 31, 2023, and December 31, 2022, the Company had reserved 3,018,774 and 2,934,679 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers, and consultants pursuant to equity awards granted under the Company's 2014 Incentive Compensation Plan (the “2014 Plan”). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. There were no options granted during the three months ended March 31, 2023 and 2022. The fair value of RSUs granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee share options activity during the three months ended March 31, 2023 is as follows: Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding as of December 31, 2022 43,994 $ 41.27 4.39 $ - Granted - - - - Exercised - - - - Forfeited (32 ) 32.93 - - Options outstanding as of March 31, 2023 43,962 $ 41.27 4.13 $ - Options exercisable as of March 31, 2023 43,962 $ 41.27 4.13 $ - The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the three months ended March 31, 2023 and 2022. A summary of employees and non-employees RSUs activity during the three months ended March 31, 2023 is as follows: Number of shares underlying outstanding RSUs Weighted average grant date fair value Unvested RSUs as of December 31, 2022 2,755,057 $ 1.16 Granted 5,000 0.80 Vested (122,056 ) 1.05 Forfeited (89,063 ) 1.19 Unvested RSUs as of March 31, 2023 2,548,938 $ 1.16 The weighted average grant date fair value of RSUs granted during the three months ended March 31, 2023, and 2022 was $0.80 and $1.12, respectively. As of March 31, 2023, there were $2.3 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2014 Plan. This cost is expected to be recognized over a period of approximately 2.7 years. The number of options and RSUs outstanding as of March 31, 2023 is set forth below, with options separated by range of exercise price. Range of exercise price Options and RSUs outstanding as of March 31, 2023 Weighted average remaining contractual life (years) (1) Options outstanding and exercisable as of March 31, 2023 Weighted average remaining contractual life (years) (1) RSUs only 2,548,938 - - - $5.37 12,425 5.99 12,425 5.99 $20.42 - $33.75 13,285 4.98 13,285 4.98 $37.14 - $38.75 8,946 0.66 8,946 0.66 $50 - $52.50 6,731 4.22 6,731 4.22 $182.5 - $524 2,575 2.60 2,575 2.60 2,592,900 4.13 43,962 4.13 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. b. Share-based awards to non-employee consultants: As of March 31, 2023, there are no outstanding options or RSUs held by non-employee consultants. c. Treasury shares: On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8.0 million of its Ordinary Shares, par value NIS 0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, the Company’s Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and will expire on the earlier of August 9, 2023, or reaching the additional $5.8 million of repurchases of ordinary shares. As of March 31, 2023, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 3,663,558 of its outstanding ordinary shares at a total cost of $3.3 million. d. Warrants to purchase ordinary shares: The following table summarizes information about warrants outstanding and exercisable that were classified as equity as of March 31, 2023: Issuance date Warrants outstanding Exercise price per warrant Warrants outstanding and exercisable Contractual term (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) December 28, 2016 (2) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (3) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (4) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (5) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (6) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (7) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019, and June 6, 2019 (8) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (9) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (10) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (11) 50,000 $ 7.500 50,000 June 10, 2024 February 10, 2020 (12) 28,400 $ 1.250 28,400 February 10, 2025 February 10, 2020 (13) 105,840 $ 1.563 105,840 February 10, 2025 July 6, 2020 (14) 448,698 $ 1.760 448,698 January 2, 2026 July 6, 2020 (15) 296,297 $ 2.278 296,297 January 2, 2026 December 8, 2020 (16) 586,760 $ 1.340 586,760 June 8, 2026 December 8, 2020 (17) 108,806 $ 1.792 108,806 June 8, 2026 February 26, 2021 (18) 5,460,751 $ 3.600 5,460,751 August 26, 2026 February 26, 2021 (19) 655,290 $ 4.578 655,290 August 26, 2026 September 29, 2021 (20) 8,006,759 $ 2.000 8,006,759 March 29, 2027 September 29, 2021 (21) 960,811 $ 2.544 960,811 September 27, 2026 19,420,894 19,420,894 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2023. (2) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (3) Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018. (4) Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018. (5) Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019. (6) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. (7) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. (8) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. (9) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. (10) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (11) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants. (12) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of March 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the three months that ended March 31, 2023, no warrants were exercised. (13) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of March 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the three months that ended March 31, 2023, no warrants were exercised. (14) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of March 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the three months that ended March 31, 2023, no warrants were exercised. (15) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. (16) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of March 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the three months that ended March 31, 2023, no warrants were exercised. (17) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of March 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the three months that ended March 31, 2023, no warrants were exercised. (18) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021. (19) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement. (20) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. (21) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering. e. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense for both employees and non-employees in the condensed consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2023 2022 Cost of revenues $ (2 ) $ 3 Research and development, net 32 16 Sales and marketing 81 51 General and administrative 193 83 Total $ 304 $ 153

FINANCIAL EXPENSES (INCOME), NE

FINANCIAL EXPENSES (INCOME), NET	3 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES (INCOME), NET	NOTE 8: FINANCIAL EXPENSES (INCOME), NET The components of financial expenses (income), net were as follows (in thousands): Three Months Ended March 31, 2023 2022 Foreign currency transactions and other $ (13 ) $ 15 Interest income (73 ) - Bank commissions 8 9 $ (78 ) $ 24

GEOGRAPHIC INFORMATION AND MAJO

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 9: GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from selling systems and services. The following is a summary of revenues within geographic areas (in thousands): Three Months Ended March 31, 2023 2022 Revenues based on customer’s location: United States $ 877 $ 220 Europe 324 647 Asia-Pacific 28 8 Africa 1 1 Total revenues $ 1,230 $ 876 March 31, December 31, 2023 2022 Long-lived assets by geographic region (*): Israel $ 704 $ 757 United States 675 231 Germany 31 44 $ 1,410 $ 1,032 (*) Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets. Three Months Ended March 31, 2023 2022 Major customer data as a percentage of total revenues: Customer A 23 % 18 % Customer B 10 % * ) Customer C 10 % * ) Customer D 10 % * ) Customer E * ) 14 % Customer F * ) 13 % Customer G * ) 11 % Customer H * ) 10 % Customer I * ) 10 % *) Less than 10%.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Revenue Recognition	a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended March 31, 2023 2022 Units placed $ 1,126 $ 778 Spare parts and warranties 104 98 Total Revenues $ 1,230 $ 876 Units placed During the periods for the three months ended March 31, 2023 and 2022, the Company offered five products: (1) ReWalk Personal; (2) ReWalk Rehabilitation; (3) ReStore; (4) MyoCycle; and (5) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023. ReWalk Personal and ReWalk Rehabilitation are SCI Products, which are currently designed for everyday use by paraplegic individuals at home and in their communities. The SCI Products are custom fitted for each user, as well as for use by paraplegic patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReWalk Rehabilitation which is a ReWalk Personal 6.0 product sold with multiple sizes of our adjustable parts to allow different users the ability to train within a clinic. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. The Company also sells Distributed Products that include the MyoCycle, which uses Functional Electrical Stimulation (“FES”) technology, and previously MediTouch tutor movement biofeedback devices. The Company markets the Distributed Products in the United States for use at home or in clinic. On January 31, 2023, the Company terminated the distribution agreement with MediTouch. Units placed includes revenue from sales of SCI Products, ReStore and the Distributed Products. For units placed, the Company recognizes revenue when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model. SCI Products include a five-year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty. The ReStore device is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are sold with an assurance-type warranty ranging from one year to ten years depending on the specific product and part. Contract balances (in thousands) March 31, December 31, 2023 2022 Trade receivable, net of credit losses (1) $ 532 $ 1,036 Deferred revenues (1) (2) $ 1,252 $ 1,191 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the three months ended March 31, 2023, $128 thousand of the December 31, 2022 deferred revenues balance was recognized as revenues. Deferred revenue is composed primarily of unearned revenue related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company’s unearned performance obligations as of March 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.2 million, which will be fulfilled over one to five years.
Concentrations of Credit Risks:	b. Concentrations of Credit Risks: The below table reflects the concentration of credit risk for the Company’s current customers as of the quarter ended March 31, 2023, to which substantial sales were made: March 31, December 31, 2023 2022 Customer A 28 % 27 % Customer B 24 % 13 % Customer C * ) 13 % Customer D * ) 11 % *) Less than 10% The allowance for credit losses is based on the Company’s assessment of the collectability of accounts. The Company regularly assessed collectability based on a combination of factors, including an assessment of the current customer’s aging balance, the nature and size of the customer, the financial condition of the customer, and future expected economic conditions. Trade receivables deemed uncollectable are charged against the allowance for credit losses when identified. As of March 31, 2023 and December 31, 2022, trade receivables are presented net of allowance for credit losses in the amount of $26 thousand.
Warranty provision	c. Warranty provision For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars Balance at December 31, 2022 $ 92 Provision 87 Usage (90 ) Balance at March 31, 2023 $ 89
Basic and diluted net loss per ordinary share	d. Basic and diluted net loss per ordinary share: Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive. For the three months ended March 31, 2023 and 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,464,856 and 19,420,894, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
New Accounting Pronouncements	e. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Financial Instruments In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of disaggregation of revenues	Three Months Ended March 31, 2023 2022 Units placed $ 1,126 $ 778 Spare parts and warranties 104 98 Total Revenues $ 1,230 $ 876
Schedule of contract balances	March 31, December 31, 2023 2022 Trade receivable, net of credit losses (1) $ 532 $ 1,036 Deferred revenues (1) (2) $ 1,252 $ 1,191 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) During the three months ended March 31, 2023, $128 thousand of the December 31, 2022 deferred revenues balance was recognized as revenues.
Schedule of concentration of credit risk	March 31, December 31, 2023 2022 Customer A 28 % 27 % Customer B 24 % 13 % Customer C * ) 13 % Customer D * ) 11 % *) Less than 10%
Schedule of product warranty liability	US Dollars Balance at December 31, 2022 $ 92 Provision 87 Usage (90 ) Balance at March 31, 2023 $ 89

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of inventories	March 31, December 31, 2023 2022 Finished products $ 2,519 $ 2,421 Raw materials 508 508 $ 3,027 $ 2,929

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	2023 $ 503 2024 638 2025 295 2026 1 Total lease payments 1,437 Less: imputed interest (156 ) Present value of future lease payments 1,281 Less: current maturities of operating leases (624 ) Non-current operating leases $ 657 Weighted-average remaining lease term (in years) 2.18 Weighted-average discount rate 9.9 %

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2023
Share-based Payment Arrangement [Abstract]
Schedule of employee options activity	Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding as of December 31, 2022 43,994 $ 41.27 4.39 $ - Granted - - - - Exercised - - - - Forfeited (32 ) 32.93 - - Options outstanding as of March 31, 2023 43,962 $ 41.27 4.13 $ - Options exercisable as of March 31, 2023 43,962 $ 41.27 4.13 $ -
Schedule of employee RSUs activity	Number of shares underlying outstanding RSUs Weighted average grant date fair value Unvested RSUs as of December 31, 2022 2,755,057 $ 1.16 Granted 5,000 0.80 Vested (122,056 ) 1.05 Forfeited (89,063 ) 1.19 Unvested RSUs as of March 31, 2023 2,548,938 $ 1.16
Schedule of options and RSUs outstanding	Range of exercise price Options and RSUs outstanding as of March 31, 2023 Weighted average remaining contractual life (years) (1) Options outstanding and exercisable as of March 31, 2023 Weighted average remaining contractual life (years) (1) RSUs only 2,548,938 - - - $5.37 12,425 5.99 12,425 5.99 $20.42 - $33.75 13,285 4.98 13,285 4.98 $37.14 - $38.75 8,946 0.66 8,946 0.66 $50 - $52.50 6,731 4.22 6,731 4.22 $182.5 - $524 2,575 2.60 2,575 2.60 2,592,900 4.13 43,962 4.13 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	(6) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. (7) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. (8) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. (9) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. (10) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. (11) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants. (12) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of March 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the three months that ended March 31, 2023, no warrants were exercised. (13) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of March 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the three months that ended March 31, 2023, no warrants were exercised. (14) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of March 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the three months that ended March 31, 2023, no warrants were exercised. (15) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. (16) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of March 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the three months that ended March 31, 2023, no warrants were exercised. (17) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of March 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the three months that ended March 31, 2023, no warrants were exercised. (18) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021. (19) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement. (20) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. (21) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
Schedule of non-cash share-based compensation expense	Three Months Ended March 31, 2023 2022 Cost of revenues $ (2 ) $ 3 Research and development, net 32 16 Sales and marketing 81 51 General and administrative 193 83 Total $ 304 $ 153

FINANCIAL EXPENSES (INCOME), _2

FINANCIAL EXPENSES (INCOME), NET (Tables)	3 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	Three Months Ended March 31, 2023 2022 Foreign currency transactions and other $ (13 ) $ 15 Interest income (73 ) - Bank commissions 8 9 $ (78 ) $ 24

GEOGRAPHIC INFORMATION AND MA_2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	Three Months Ended March 31, 2023 2022 Revenues based on customer’s location: United States $ 877 $ 220 Europe 324 647 Asia-Pacific 28 8 Africa 1 1 Total revenues $ 1,230 $ 876
Schedule of long-lived assets by geographic region	March 31, December 31, 2023 2022 Long-lived assets by geographic region (*): Israel $ 704 $ 757 United States 675 231 Germany 31 44 $ 1,410 $ 1,032 (*) Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.
Schedule of major customer data as a percentage of total revenues	Three Months Ended March 31, 2023 2022 Major customer data as a percentage of total revenues: Customer A 23 % 18 % Customer B 10 % * ) Customer C 10 % * ) Customer D 10 % * ) Customer E * ) 14 % Customer F * ) 13 % Customer G * ) 11 % Customer H * ) 10 % Customer I * ) 10 % *) Less than 10%.

GENERAL (Details)

GENERAL (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
General (Textual)
Net loss	$ 4,321	$ 4,350
Accumulated deficit	218,071		$ 213,750
Cash and cash equivalents	61,883		$ 67,896
Negative cash flow from operations	$ (5,233)	$ (5,708)

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total Revenues	$ 1,230	$ 876
Units placed [Member]
Total Revenues	1,126	778
Spare parts and warranties [Member]
Total Revenues	$ 104	$ 98

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Trade receivable, net of credit losses	[1]	$ 532	$ 1,036
Deferred revenues	[1],[2]	$ 1,252	$ 1,191
[1]Balance presented net of unrecognized revenues that were not yet collected.[2]During the three months ended March 31, 2023, $128 thousand of the December 31, 2022 deferred revenues balance was recognized as revenues.

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - Trade Receivables [Member] - Credit Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2023		Dec. 31, 2022
Customer A [Member]
Concentration Risk [Line Items]
Concentration of credit risk	28%		27%
Customer B [Member]
Concentration Risk [Line Items]
Concentration of credit risk	24%		13%
Customer C [Member]
Concentration Risk [Line Items]
Concentration of credit risk			13%	[1]
Customer D [Member]
Concentration Risk [Line Items]
Concentration of credit risk		[1]	11%
[1]Less than 10%

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details 3) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Warranty provision:
Balance at December 31, 2022	$ 92
Provision	87
Usage	(90)
Balance at March 31, 2023	$ 89

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Significant Accounting Policies (Textual)
Deferred revenues recognized	$ 128
Allowance for credit losses	$ 26
Number of ordinary shares excluded from the calculations of diluted loss per share	19,464,856	19,420,894
Revenue recognition description	the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.2 million, which will be fulfilled over one to five years.
Distributed Products [Member] | Minimum [Member]
Significant Accounting Policies (Textual)
Service policy	1 year
Distributed Products [Member] | Maximum [Member]
Significant Accounting Policies (Textual)
Service policy	10 years

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished products	$ 2,519	$ 2,421
Raw materials	508	508
Inventories	$ 3,027	$ 2,929

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2023	$ 503
2024	638
2025	295
2026	1
Total lease payments	1,437
Less: imputed interest	(156)
Present value of future lease payments	1,281
Less: current maturities of operating leases	(624)	$ (564)
Non-current operating leases	$ 657	$ 333
Weighted-average remaining lease term (in years)	2 years 2 months 4 days
Weighted-average discount rate	9.90%

COMMITMENTS AND CONTINGENT LI_4

COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Commitments and Contingent Liabilities (Textual)
Lease expense	$ 192	$ 179
Non-cancelable outstanding obligations	2,100
Total fund received	349
Royalties expenses	$ 0	$ 3
Lease expiration, term	The Company operates from leased facilities in Israel, the United States and Germany. These leases expire in 2025.
Other long-term assets	$ 657
IPO [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio	ordinary shares in a conversion ratio of 1 to 1
RRL and RRG [Member]
Commitments and Contingent Liabilities (Textual)
Maximum penalties payable on early release of agreement	$ 21
Lease expiration, term	RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates between 2023 and 2026.
Israel Innovation Authority ("IIA") [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received	$ 2,300
Royalty bearing grants	1,600
Royalties paid	$ 110
Percentage of obligation to pay royalties	3%
Contingent liability	$ 1,600
Percentage of grant received	100%
Israel Innovation Authority ("IIA") [Member] | Convertible preferred A shares [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares	$ 400
Convertible preferred shares	209

RESEARCH COLLABORATION AGREEM_2

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Research Collaboration Agreement and License Agreement (Textual)
Research and development, net	$ 752	$ 907
Harvard License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Research and development, net	$ 11	$ 10

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-based Payment Arrangement [Abstract]
Number, Options outstanding as of December 31, 2022	43,994
Number, Granted	0
Number, Exercised	0
Number, Forfeited	(32)
Number, Options outstanding as of March 31, 2023	43,962	43,994
Number, Options exercisable as of March 31, 2023	43,962
Average exercise price, Options outstanding as of December 31, 2022	$ 41.27
Average exercise price, Granted	0
Average exercise price, Exercised	0
Average exercise price, Forfeited	32.93
Average exercise price, Options outstanding as of March 31, 2023	41.27	$ 41.27
Average exercise price, Options exercisable as of March 31, 2023	$ 41.27
Average remaining contractual life (in years), Options outstanding as of December 31, 2022	4 years 1 month 17 days	4 years 4 months 20 days
Average remaining contractual life (in years), Options exercisable as of March 31, 2023	4 years 1 month 17 days
Aggregate intrinsic value (in thousands), Options outstanding	$ 0	$ 0
Aggregate intrinsic value (in thousands), Options exercisable as of March 31, 2023	$ 0

SHAREHOLDERS' EQUITY (Details 1

SHAREHOLDERS' EQUITY (Details 1) - Employee and Non-Employee RSUs [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of shares underlying outstanding RSUs
Unvested RSUs as of December 31, 2022 | shares	2,755,057
Granted | shares	5,000
Vested | shares	(122,056)
Forfeited | shares	(89,063)
Unvested RSUs as of March 31, 2023 | shares	2,548,938
Weighted average grant date fair value
Unvested RSUs as of December 31, 2022 | $ / shares	$ 1.16
Granted | $ / shares	0.8
Vested | $ / shares	1.05
Forfeited | $ / shares	1.19
Unvested RSUs as of March 31, 2023 | $ / shares	$ 1.16

SHAREHOLDERS' EQUITY (Details 2

SHAREHOLDERS' EQUITY (Details 2) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,592,900
Options outstanding weighted average remaining contractual life (years)	4 years 1 month 17 days	[1]
Options outstanding and exercisable	43,962
Options exercisable weighted average remaining contractual life (years)	4 years 1 month 17 days	[1]
RSUs only [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,548,938
Options outstanding and exercisable	0
5.37 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 5.37
Options outstanding	12,425
Options outstanding weighted average remaining contractual life (years)	5 years 11 months 26 days	[1]
Options outstanding and exercisable	12,425
Options exercisable weighted average remaining contractual life (years)	5 years 11 months 26 days	[1]
20.42 - 33.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 20.42
Range of exercise price, maximum | $ / shares	$ 33.75
Options outstanding	13,285
Options outstanding weighted average remaining contractual life (years)	4 years 11 months 23 days	[1]
Options outstanding and exercisable	13,285
Options exercisable weighted average remaining contractual life (years)	4 years 11 months 23 days	[1]
37.14 - 38.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 37.14
Range of exercise price, maximum | $ / shares	$ 38.75
Options outstanding	8,946
Options outstanding weighted average remaining contractual life (years)	7 months 28 days	[1]
Options outstanding and exercisable	8,946
Options exercisable weighted average remaining contractual life (years)	7 months 28 days	[1]
50 - 52.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 50
Range of exercise price, maximum | $ / shares	$ 52.5
Options outstanding	6,731
Options outstanding weighted average remaining contractual life (years)	4 years 2 months 19 days	[1]
Options outstanding and exercisable	6,731
Options exercisable weighted average remaining contractual life (years)	4 years 2 months 19 days	[1]
182.5 - 524 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 182.5
Range of exercise price, maximum | $ / shares	$ 524
Options outstanding	2,575
Options outstanding weighted average remaining contractual life (years)	2 years 7 months 6 days	[1]
Options outstanding and exercisable	2,575
Options exercisable weighted average remaining contractual life (years)	2 years 7 months 6 days	[1]
[1]Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

SHAREHOLDERS' EQUITY (Details 3

SHAREHOLDERS' EQUITY (Details 3)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants outstanding	19,420,894
Warrants outstanding and exercisable	19,420,894
December 31, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	4,771	[1]
Exercise price per warrant | $ / shares	$ 7.5	[1]
Warrants outstanding and exercisable	4,771	[1]
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,908	[2]
Exercise price per warrant | $ / shares	$ 7.5	[2]
Warrants outstanding and exercisable	1,908	[2]
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	126,839	[3]
Exercise price per warrant | $ / shares	$ 7.5	[3]
Warrants outstanding and exercisable	126,839	[3]
Contractual term	Nov. 20, 2023	[3]
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	106,680	[4]
Exercise price per warrant | $ / shares	$ 9.375	[4]
Warrants outstanding and exercisable	106,680	[4]
Contractual term	Nov. 15, 2023	[4]
February 25, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	45,600	[5]
Exercise price per warrant | $ / shares	$ 7.187	[5]
Warrants outstanding and exercisable	45,600	[5]
Contractual term	Feb. 21, 2024	[5]
April 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	408,457	[6]
Exercise price per warrant | $ / shares	$ 5.14	[6]
Warrants outstanding and exercisable	408,457	[6]
Contractual term	Oct. 07, 2024	[6]
April 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	49,015	[7]
Exercise price per warrant | $ / shares	$ 6.503	[7]
Warrants outstanding and exercisable	49,015	[7]
Contractual term	Apr. 03, 2024	[7]
June 5, 2019 and June 6, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,464,665	[8]
Exercise price per warrant | $ / shares	$ 7.5	[8]
Warrants outstanding and exercisable	1,464,665	[8]
Contractual term	Jun. 05, 2024	[8]
June 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	87,880	[9]
Exercise price per warrant | $ / shares	$ 9.375	[9]
Warrants outstanding and exercisable	87,880	[9]
Contractual term	Jun. 05, 2024	[9]
June 12, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	416,667	[10]
Exercise price per warrant | $ / shares	$ 6	[10]
Warrants outstanding and exercisable	416,667	[10]
Contractual term	Dec. 12, 2024	[10]
June 10, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	50,000	[11]
Exercise price per warrant | $ / shares	$ 7.5	[11]
Warrants outstanding and exercisable	50,000	[11]
Contractual term	Jun. 10, 2024	[11]
February 10, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	28,400	[12]
Exercise price per warrant | $ / shares	$ 1.25	[12]
Warrants outstanding and exercisable	28,400	[12]
Contractual term	Feb. 10, 2025	[12]
February 10, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	105,840	[13]
Exercise price per warrant | $ / shares	$ 1.563	[13]
Warrants outstanding and exercisable	105,840	[13]
Contractual term	Feb. 10, 2025	[13]
July 6, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	448,698	[14]
Exercise price per warrant | $ / shares	$ 1.76	[14]
Warrants outstanding and exercisable	448,698	[14]
Contractual term	Jan. 02, 2026	[14]
July 6, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	296,297	[15]
Exercise price per warrant | $ / shares	$ 2.278	[15]
Warrants outstanding and exercisable	296,297	[15]
Contractual term	Jan. 02, 2026	[15]
December 8, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	586,760	[16]
Exercise price per warrant | $ / shares	$ 1.34	[16]
Warrants outstanding and exercisable	586,760	[16]
Contractual term	Jun. 08, 2026	[16]
December 8, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	108,806	[17]
Exercise price per warrant | $ / shares	$ 1.792	[17]
Warrants outstanding and exercisable	108,806	[17]
Contractual term	Jun. 08, 2026	[17]
February 26, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	5,460,751	[18]
Exercise price per warrant | $ / shares	$ 3.6	[18]
Warrants outstanding and exercisable	5,460,751	[18]
Contractual term	Aug. 26, 2026	[18]
February 26, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	655,290	[19]
Exercise price per warrant | $ / shares	$ 4.578	[19]
Warrants outstanding and exercisable	655,290	[19]
Contractual term	Aug. 26, 2026	[19]
September 29, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	8,006,759	[20]
Exercise price per warrant | $ / shares	$ 2	[20]
Warrants outstanding and exercisable	8,006,759	[20]
Contractual term	Mar. 29, 2027	[20]
September 29, 2021 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	960,811	[21]
Exercise price per warrant | $ / shares	$ 2.544	[21]
Warrants outstanding and exercisable	960,811	[21]
Contractual term	Sep. 27, 2026	[21]
[1]Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2023.[2]Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.[3]Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.[4]Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.[5]Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.[6]Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.[7]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.[8]Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.[9]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.[10]Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.[11]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.[12]Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of March 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the three months that ended March 31, 2023, no warrants were exercised.[13]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of March 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the three months that ended March 31, 2023, no warrants were exercised.[14]Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of March 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the three months that ended March 31, 2023, no warrants were exercised.[15]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.[16]Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of March 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the three months that ended March 31, 2023, no warrants were exercised.[17]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of March 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the three months that ended March 31, 2023, no warrants were exercised.[18]Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.[19]Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.[20]Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.[21]Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.

SHAREHOLDERS' EQUITY (Details 4

SHAREHOLDERS' EQUITY (Details 4) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 304	$ 153
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	(2)	3
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	32	16
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	81	51
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 193	$ 83

SHAREHOLDERS' EQUITY (Details T

SHAREHOLDERS' EQUITY (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 $ / shares	Dec. 31, 2015 $ / shares	Mar. 31, 2023 ₪ / shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2022 ₪ / shares shares	Dec. 22, 2022 USD ($)	Jul. 21, 2022 USD ($)	Jun. 02, 2022 ₪ / shares	Jun. 02, 2022 USD ($)	Dec. 28, 2016 USD ($)
Shareholders' Equity (Textual)
Per share value of stock repurchase authorized | ₪ / shares				₪ 0.25		₪ 0.25
Certain institutional purchasers [Member] | Offering of ordinary shares in February 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued | shares					3,740,100
Proceeds from warrants	$ 4,675,125
Certain institutional purchasers [Member] | Registered direct offering of ordinary shares in July 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued | shares					2,020,441
Proceeds from warrants	3,555,976
Certain institutional purchasers [Member] | Offering of ordinary shares in December 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued | shares					3,598,072
Proceeds from warrants	4,821,416
Placement agent [Member] | February 2020 best efforts offering [Member]
Shareholders' Equity (Textual)
Number of warrants issued | shares					230,160
Proceeds from warrants	359,625
Placement agent [Member] | December 2020 private placement [Member]
Shareholders' Equity (Textual)
Number of warrants issued | shares					225,981
Proceeds from warrants	$ 405,003
Kreos Capital V [Member]
Shareholders' Equity (Textual)
Warrants grant date			Dec. 31, 2015
Warrants exercisable, description	currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2023.
Kreos Capital [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares			$ 7.5
Drawdown amount under loan agreement											$ 8,000
Employee Stock Option [Member]
Shareholders' Equity (Textual)
Award vesting period, description	Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.
Shares reserved for future issuance (in shares) | shares					3,018,774	2,934,679
Unrecognized cost of shares					$ 2,300
Expected term of shares	2 years 8 months 12 days
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Weighted average grant date fair value, options (in USD per share) | $ / shares	$ 0.8	$ 1.12
Share repurchase program [Member]
Shareholders' Equity (Textual)
Authorized value of stock repurchased							$ 5,800	$ 8,000		$ 8,000
Per share value of stock repurchase authorized | ₪ / shares									₪ 0.25
Treasury Stock, Shares | shares					3,663,558
Total cost	$ 3,300

FINANCIAL EXPENSES (INCOME), _3

FINANCIAL EXPENSES (INCOME), NET (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ (13)	$ 15
Interest income	(73)	0
Bank commissions	8	9
Financial expenses (income), net	$ (78)	$ 24

GEOGRAPHIC INFORMATION AND MA_3

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue, Major Customer [Line Items]
Total revenues	$ 1,230	$ 876
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	877	220
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	324	647
Asia-Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	28	8
Africa [Member]
Revenue, Major Customer [Line Items]
Total revenues	$ 1	$ 1

GEOGRAPHIC INFORMATION AND MA_4

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets		$ 1,410	$ 1,032
Israel [Mmeber]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	704	757
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	675	231
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 31	$ 44
[1]Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.

GEOGRAPHIC INFORMATION AND MA_5

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) - Sales Revenue, Net [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023		Mar. 31, 2022
Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration risk	23%		18%
Customer B [Member]
Revenue, Major Customer [Line Items]
Concentration risk	10%			[1]
Customer C [Member]
Revenue, Major Customer [Line Items]
Concentration risk	10%			[1]
Customer D [Member]
Revenue, Major Customer [Line Items]
Concentration risk	10%			[1]
Customer E [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	14%
Customer F [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	13%
Customer G [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	11%
Customer H [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	10%
Customer I [Member]
Revenue, Major Customer [Line Items]
Concentration risk		[1]	10%
[1]Less than 10%.

GEOGRAPHIC INFORMATION AND MA_6

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)	3 Months Ended
	Mar. 31, 2023 segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1